Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
暂无分享,去创建一个
G. Sonpavde | M. Galsky | D. V. Von Hoff | M. Fleming | A. Aparicio | W. Berry | Lianchun Xiao | L. Asmar | L. Garbo | R. Delaune | K. Boehm | F. Zhan | S. Rousey | R. Weinstein | B. North
[1] Vincenza Dolo,et al. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. , 2009, Endocrine-related cancer.
[2] Peter A. Jones,et al. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors , 2009, Epigenetics.
[3] Vincenza Dolo,et al. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen‐independent prostate cancer cells , 2008, The Prostate.
[4] R. Rees,et al. DNA demethylation and histone deacetylation inhibition co‐operate to re‐express estrogen receptor beta and induce apoptosis in prostate cancer cell‐lines , 2008, The Prostate.
[5] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Lowrey,et al. Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. , 2007, Blood.
[7] I. Tannock,et al. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.
[8] Andreas Schätzlein,et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Nemunaitis,et al. Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.
[10] B. Trock,et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. , 2007, The Journal of urology.
[11] R. C. Coombes,et al. The Importance of Careful Blood Processing in Isolation of Cell‐Free DNA , 2006, Annals of the New York Academy of Sciences.
[12] D. Hoon,et al. Comparative Analysis of Mesenteric and Peripheral Blood Circulating Tumor DNA in Colorectal Cancer Patients , 2006, Annals of the New York Academy of Sciences.
[13] R. Larson,et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Kelly B. Moran,et al. Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma , 2006, Clinical Cancer Research.
[15] J. Manola,et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Issa,et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. , 2006, Cancer research.
[17] C. Tangen,et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.
[18] A. Partin,et al. Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy , 2005, Clinical Cancer Research.
[19] Y. Saunthararajah,et al. DNA hypo‐methylating agents and sickle cell disease , 2004, British journal of haematology.
[20] L. Ossowski,et al. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line , 2004, Oncogene.
[21] J. Issa,et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.
[22] J. Christman,et al. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.
[23] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[24] D. V. Von Hoff,et al. 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells. , 1999, Anticancer research.
[25] J. Herman,et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. , 1998, Cancer research.
[26] D. Samid,et al. A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer , 1998, Tumori.
[27] M. van Glabbeke,et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. , 1987, European journal of cancer & clinical oncology.
[28] T. Ley,et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. , 1982, The New England journal of medicine.
[29] J. M. Buchanan,et al. The wolf in the cello , 1973 .
[30] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .